612 related articles for article (PubMed ID: 30970186)
1. Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease.
Egan MF; Kost J; Voss T; Mukai Y; Aisen PS; Cummings JL; Tariot PN; Vellas B; van Dyck CH; Boada M; Zhang Y; Li W; Furtek C; Mahoney E; Harper Mozley L; Mo Y; Sur C; Michelson D
N Engl J Med; 2019 Apr; 380(15):1408-1420. PubMed ID: 30970186
[TBL] [Abstract][Full Text] [Related]
2. Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease.
Egan MF; Kost J; Tariot PN; Aisen PS; Cummings JL; Vellas B; Sur C; Mukai Y; Voss T; Furtek C; Mahoney E; Harper Mozley L; Vandenberghe R; Mo Y; Michelson D
N Engl J Med; 2018 May; 378(18):1691-1703. PubMed ID: 29719179
[TBL] [Abstract][Full Text] [Related]
3. BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer's disease brain.
Sur C; Kost J; Scott D; Adamczuk K; Fox NC; Cummings JL; Tariot PN; Aisen PS; Vellas B; Voss T; Mahoney E; Mukai Y; Kennedy ME; Lines C; Michelson D; Egan MF
Brain; 2020 Dec; 143(12):3816-3826. PubMed ID: 33253354
[TBL] [Abstract][Full Text] [Related]
4. Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer's disease.
Egan MF; Mukai Y; Voss T; Kost J; Stone J; Furtek C; Mahoney E; Cummings JL; Tariot PN; Aisen PS; Vellas B; Lines C; Michelson D
Alzheimers Res Ther; 2019 Aug; 11(1):68. PubMed ID: 31387606
[TBL] [Abstract][Full Text] [Related]
5. Lessons that can be learnt from the failure of verubecestat in Alzheimer's disease.
Doggrell SA
Expert Opin Pharmacother; 2019 Dec; 20(17):2095-2099. PubMed ID: 31423903
[No Abstract] [Full Text] [Related]
6. Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-AβPPswe Mice Without Inducing Microhemorrhage.
Villarreal S; Zhao F; Hyde LA; Holder D; Forest T; Sondey M; Chen X; Sur C; Parker EM; Kennedy ME
J Alzheimers Dis; 2017; 59(4):1393-1413. PubMed ID: 28800329
[TBL] [Abstract][Full Text] [Related]
7. Retinal Optical Coherence Tomography Metrics Are Unchanged in Verubecestat Alzheimer's Disease Clinical Trial but Correlate with Baseline Regional Brain Atrophy.
Sergott RC; Raji A; Kost J; Sur C; Jackson S; Locco A; Patel A; Furtek C; Mattson B; Egan MF
J Alzheimers Dis; 2021; 79(1):275-287. PubMed ID: 33252075
[TBL] [Abstract][Full Text] [Related]
8. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).
Salloway S; Honigberg LA; Cho W; Ward M; Friesenhahn M; Brunstein F; Quartino A; Clayton D; Mortensen D; Bittner T; Ho C; Rabe C; Schauer SP; Wildsmith KR; Fuji RN; Suliman S; Reiman EM; Chen K; Paul R
Alzheimers Res Ther; 2018 Sep; 10(1):96. PubMed ID: 30231896
[TBL] [Abstract][Full Text] [Related]
9. Progression from Prodromal Alzheimer's Disease to Mild Alzheimer's Disease Dementia in the Verubecestat APECS Study: Adjudicating Diagnostic Transitions.
Voss T; Kost J; Mercer SP; Furtek C; Randolph C; Lines C; Egan MF; Cummings JL
J Alzheimers Dis; 2023; 92(1):341-348. PubMed ID: 36744336
[TBL] [Abstract][Full Text] [Related]
10. Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease.
Honig LS; Vellas B; Woodward M; Boada M; Bullock R; Borrie M; Hager K; Andreasen N; Scarpini E; Liu-Seifert H; Case M; Dean RA; Hake A; Sundell K; Poole Hoffmann V; Carlson C; Khanna R; Mintun M; DeMattos R; Selzler KJ; Siemers E
N Engl J Med; 2018 Jan; 378(4):321-330. PubMed ID: 29365294
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA;
Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517
[TBL] [Abstract][Full Text] [Related]
12. Lecanemab in Early Alzheimer's Disease.
van Dyck CH; Swanson CJ; Aisen P; Bateman RJ; Chen C; Gee M; Kanekiyo M; Li D; Reyderman L; Cohen S; Froelich L; Katayama S; Sabbagh M; Vellas B; Watson D; Dhadda S; Irizarry M; Kramer LD; Iwatsubo T
N Engl J Med; 2023 Jan; 388(1):9-21. PubMed ID: 36449413
[TBL] [Abstract][Full Text] [Related]
13. Donanemab in Early Alzheimer's Disease.
Mintun MA; Lo AC; Duggan Evans C; Wessels AM; Ardayfio PA; Andersen SW; Shcherbinin S; Sparks J; Sims JR; Brys M; Apostolova LG; Salloway SP; Skovronsky DM
N Engl J Med; 2021 May; 384(18):1691-1704. PubMed ID: 33720637
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease.
Frölich L; Wunderlich G; Thamer C; Roehrle M; Garcia M; Dubois B
Alzheimers Res Ther; 2019 Feb; 11(1):18. PubMed ID: 30755255
[TBL] [Abstract][Full Text] [Related]
15. Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease.
Wessels AM; Lines C; Stern RA; Kost J; Voss T; Mozley LH; Furtek C; Mukai Y; Aisen PS; Cummings JL; Tariot PN; Vellas B; Dupre N; Randolph C; Michelson D; Andersen SW; Shering C; Sims JR; Egan MF
Alzheimers Dement; 2020 Nov; 16(11):1483-1492. PubMed ID: 33049114
[TBL] [Abstract][Full Text] [Related]
16. A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease.
Ostrowitzki S; Lasser RA; Dorflinger E; Scheltens P; Barkhof F; Nikolcheva T; Ashford E; Retout S; Hofmann C; Delmar P; Klein G; Andjelkovic M; Dubois B; Boada M; Blennow K; Santarelli L; Fontoura P;
Alzheimers Res Ther; 2017 Dec; 9(1):95. PubMed ID: 29221491
[TBL] [Abstract][Full Text] [Related]
17. Neuropathology of a patient with Alzheimer disease treated with low doses of verubecestat.
Querol-Vilaseca M; Sirisi S; Molina-Porcel L; Molina B; Pegueroles J; Ferrer-Raventós P; Nuñez-Llaves R; Dols-Icardo O; Balasa M; Iulita MF; Blesa R; Belbin O; Clarimon J; Fortea J; Gelpi E; Sánchez-Valle R; Lleó A
Neuropathol Appl Neurobiol; 2022 Apr; 48(3):e12781. PubMed ID: 34825396
[TBL] [Abstract][Full Text] [Related]
18. Safety, Tolerability, and Pharmacokinetics of the β-Site Amyloid Precursor Protein-Cleaving Enzyme 1 Inhibitor Verubecestat (MK-8931) in Healthy Elderly Male and Female Subjects.
Forman M; Palcza J; Tseng J; Stone JA; Walker B; Swearingen D; Troyer MD; Dockendorf MF
Clin Transl Sci; 2019 Sep; 12(5):545-555. PubMed ID: 31215755
[TBL] [Abstract][Full Text] [Related]
19. Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.
Bateman RJ; Smith J; Donohue MC; Delmar P; Abbas R; Salloway S; Wojtowicz J; Blennow K; Bittner T; Black SE; Klein G; Boada M; Grimmer T; Tamaoka A; Perry RJ; Turner RS; Watson D; Woodward M; Thanasopoulou A; Lane C; Baudler M; Fox NC; Cummings JL; Fontoura P; Doody RS;
N Engl J Med; 2023 Nov; 389(20):1862-1876. PubMed ID: 37966285
[TBL] [Abstract][Full Text] [Related]
20. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Salloway S; Sperling R; Fox NC; Blennow K; Klunk W; Raskind M; Sabbagh M; Honig LS; Porsteinsson AP; Ferris S; Reichert M; Ketter N; Nejadnik B; Guenzler V; Miloslavsky M; Wang D; Lu Y; Lull J; Tudor IC; Liu E; Grundman M; Yuen E; Black R; Brashear HR;
N Engl J Med; 2014 Jan; 370(4):322-33. PubMed ID: 24450891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
